Superinfection during treatment of nosocomial infections with tigecycline

被引：22

作者：

Garcia-Cabrera, E.

Jimenez-Mejias, M. E. ^{[1
]}

Gil Navarro, M. V. ^{[2
]}

Gomez-Gomez, M. J. ^{[3
]}

Ortiz-Leyba, C. ^{[4
]}

Cordero, E.

Pachon, J.

机构：

[1] Hosp Univ Virgen del Rocio, Spanish Network Res Infect Dis, Infect Dis Serv, Seville 41013, Spain

[2] Hosp Univ Virgen del Rocio, Clin Pharm Serv, Seville 41013, Spain

[3] Hosp Univ Virgen del Rocio, Microbiol Serv, Seville 41013, Spain

[4] Hosp Univ Virgen del Rocio, Intens Care Serv, Seville 41013, Spain

来源：

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES | 2010年 / 29卷 / 07期

关键词：

SKIN-STRUCTURE INFECTIONS; EFFICACY; SAFETY; PHASE-3;

D O I：

10.1007/s10096-010-0942-y

中图分类号：

R51 [传染病];

学科分类号：

100201 [内科学];

摘要：

We performed a retrospective and observational study of 51 patients treated with tigecycline, as the treatment for nosocomial infections due to multidrug-resistant microorganisms, to evaluate the superinfection rate and their etiologies. Superinfections were diagnosed in 12 (23.5%) patients (seven due to Pseudomonas aeruginosa, 13.7%) and one patient had P. aeruginosa colonization. Five patients with superinfection died (41.6%), three due to superinfections and two to underlying diseases. The superinfection rate observed during tigecycline treatment is higher than that previously reported. Pseudomonas aeruginosa is the most frequent agent, being the cause of 58.5% of all superinfections.

引用

收藏

页码：867 / 871

页数：5

相关论文

共 14 条

[1]

Guidelines for the management, of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia [J].

不详 .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (04) :388-416

[2]

Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline [J].

Anthony, Kara B. ;

Fishman, Neil O. ;

Linkin, Darren R. ;

Gasink, Leanne B. ;

Edelstein, Paul H. ;

Lautenbach, Ebbing .

CLINICAL INFECTIOUS DISEASES, 2008, 46 (04) :567-570

[3]

Safety and efficacy of tigecycline in treatment of skin and skin structure infections: Results of a double-blind phase 3 comparison study with vancomycin-aztreonam [J].

Breedt, J ;

Teras, J ;

Gardovskis, J ;

Maritz, FJ ;

Vaasna, T ;

Ross, DP ;

Gioud-Paquet, M ;

Dartois, N ;

Ellis-Grosse, EJ ;

Loh, E .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) :4658-4666

[4]

Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae [J].

Daly, Michael W. ;

Riddle, David J. ;

Ledeboer, Nathan A. ;

Dunne, W. Michael ;

Ritchie, David J. .

PHARMACOTHERAPY, 2007, 27 (07) :1052-1057

[5]

Tigecycline [J].

Frampton, JE ;

Curran, MP .

DRUGS, 2005, 65 (18) :2623-2635

[6]

Gales Ana C., 2005, Braz J Infect Dis, V9, P348, DOI 10.1590/S1413-86702005000500001

[7]

Effects of efflux transporter genes on susceptibility of Escheichia coli to tigecycline (GAR-936) [J].

Hirata, T ;

Saito, A ;

Nishino, K ;

Tamura, N ;

Yamaguchi, A .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) :2179-2184

[8]

Endemic carbapenem-resistant Pseudomonas aeruginosa with acquired metallo-β-lactamase determinants in European hospital [J].

Lagatolla, C ;

Tonin, EA ;

Monti-Bragadin, C ;

Dolzani, L ;

Gombac, F ;

Bearzi, C ;

Edalucci, E ;

Gionechetti, F ;

Rossolini, GM .

EMERGING INFECTIOUS DISEASES, 2004, 10 (03) :535-538

[9]

Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates [J].

Milatovic, D ;

Schmitz, FJ ;

Verhoef, J ;

Fluit, AC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (01) :400-404

[10]

Effect of tigecycline on normal oropharyngeal and intestinal microflora [J].

Nord, Carl Erik ;

Sillerstrom, Eva ;

Wahlund, Elisabeth .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (10) :3375-3380